1-methyl-3-(3-dimethylaminopropyl)-carbodiimide | 59457-42-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-methyl-3-(3-dimethylaminopropyl)-carbodiimide
• 英文别名: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide；N1,N1-Dimethyl-N3-(methylcarbonimidoyl)-1,3-propanediamine
• CAS: 59457-42-0
• 化学式: C₇H₁₅N₃
• 分子量: 141.216
• InChiKey: UARLXRCGLWBZGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  28
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-3-(3-dimethylaminopropyl)-carbodiimide 、 碘甲烷 生成 Trimethyl-(3-methyliminomethyleneamino-propyl)-ammonium; iodide
  参考文献：
  名称：

  GERTSYUK, M. N.;SERGEEV, V. N.;TSYTOVICH, A. V.;DOLINNAYA, N. G.;KUXAR, V+, BIOORGAN. XIMIYA , 16,(1990) N, S. 1268-1276

  摘要：

  DOI：
• 作为产物：
  描述：

  1-[3-(Dimethylamino)propyl]-3-methylthiourea 生成 1-methyl-3-(3-dimethylaminopropyl)-carbodiimide
  参考文献：
  名称：

  GERTSYUK, M. N.;SERGEEV, V. N.;TSYTOVICH, A. V.;DOLINNAYA, N. G.;KUXAR, V+, BIOORGAN. XIMIYA , 16,(1990) N, S. 1268-1276

  摘要：

  DOI：

文献信息

• Substituted Spiroamide Compounds
  申请人：Schunk Stefan

  公开号：US20100234340A1

  公开（公告）日：2010-09-16

  Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q 1 , Q 2 , Q 3 , Q 4 , R 1 , R 8 , R 9a , R 9b , R 12 , R 13 , R 200 and R 210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

  对应于以下式（I）的替代螺内酰胺化合物：其中A、B、Q1、Q2、Q3、Q4、R1、R8、R9a、R9b、R12、R13、R200和R210具有定义的含义，其制备方法，包含这种化合物的药物组合物，以及利用这种化合物治疗或抑制由部分介导的疼痛或其他情况的使用布雷金肽1受体（B1R）。
• [EN] COVALENT RAS INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE RAS COVALENTS ET LEURS UTILISATIONS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2021108683A1

  公开（公告）日：2021-06-03

  The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.

  该披露涵盖化合物或其药用盐，单独或与其他治疗剂、药物组合和蛋白共轭物结合在一起，能够调节包括Ras在内的生物过程，并在癌症治疗中的用途。
• 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030139601A1

  公开（公告）日：2003-07-24

  Compounds of formula (I) and salts thereof: 1 Wherein R 1 represents methyl, ethyl, isopropyl or s-butyl; and R 2 represents hydrogen or alkyl. R 3 represents hydrogen, optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted alkynoyl, alkylsulfonyl, or alkoxycarbonyl, or R 2 and R 3 together with the nitrogen atom to which they are attached form a saturated, optionally substituted 4- to 6-membered heterocyclic ring group. The moiety -a- together with the carbon atom to which it is attached forms a 3- to 6-membered cycloalkyl group. These compounds have anthelmintic, acaricidal and insecticidal activity.

  式(I)的化合物及其盐：其中，R1代表甲基、乙基、异丙基或正丁基；R2代表氢或烷基。R3代表氢、可选择地取代的烷酰基、可选择地取代的烯酰基、可选择地取代的炔酰基、烷基磺酰基或烷氧基羰基，或者R2和R3与它们连接的氮原子一起形成饱和的、可选择地取代的4-至6-成员杂环环基。基团-a-与连接的碳原子一起形成3-至6-成员的环烷基基团。这些化合物具有驱虫、杀螨和杀虫活性。
• SEPARATING AGENT FOR IgG PURIFICATION, AND METHOD FOR PURIFYING AN IgG MONOMER USING IT
  申请人：Tosoh Corporation

  公开号：EP2012118A1

  公开（公告）日：2009-01-07

  To provide a separating agent for IgG purification, whereby IgG can be separated and purified efficiently at a high purity, and a method for purifying an IgG using it. A separating agent for IgG purification, characterized in that a polyacrylic acid and/or a polymethacrylic acid is immobilized on a carrier, and a method for purifying an IgG monomer, characterized in that a mixture containing an IgG monomer and an impurity containing polymeric IgG is contacted to the separating agent and eluted.

  提供一种用于IgG纯化的分离剂，可高效分离和纯化高纯度的IgG，以及使用该分离剂纯化IgG的方法。 一种用于纯化 IgG 的分离剂，其特征在于将聚丙烯酸和/或聚甲基丙烯酸固定在载体上；一种纯化 IgG 单体的方法，其特征在于将含有 IgG 单体和含有聚合 IgG 杂质的混合物与分离剂接触并洗脱。
• 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP2077266A1

  公开（公告）日：2009-07-08

  Provided are a compound of a formula (I) and its pharmaceutically-acceptable salt, which have a glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity. [In the formula, R1 and R2 each independently represent a lower alkyl group; X1 represent a group of a formula (II-1): (wherein R1 and R12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they are attached, R1 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH2)m, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3).]

  本发明提供了一种式（I）化合物及其药学上可接受的盐，它们具有激活葡萄糖激酶的作用，因此可用于治疗糖尿病和肥胖症。 [式中，R1 和 R2 各自独立地代表一个低级烷基；X1 代表一个式（II-1）的基团： (其中 R1 和 R12 各自独立地代表氢原子或低级烷基，或 R1 和 R12 与它们所连接的氮原子一起可形成 4 至 7 元含氮脂肪族环(构成 4 至 7 元含氮脂肪族环的一个碳原子可被氧原子取代)，或 R11 和 R12 与(CH2)m 中的一个碳原子一起可形成 4 至 7 元含氮脂肪族环;m 表示 1 至 3 的整数)]。